Table 1 Patient baseline demographics; safety set
Dose-titration phase (n= 39) | Parallel-group phase | ||
|---|---|---|---|
Lanthanum carbonate (n= 10) | Placebo (n= 11) | ||
Sex, n (%) | |||
Male | 30 (76.9) | 6 (60.0) | 8 (72.7) |
Female | 9 (23.1) | 4 (40.0) | 3 (27.3) |
Ethnicity, n (%) | |||
Asian | 1 (2.6) | 0 (0.0) | 0 (0.0) |
Caucasian | 38 (97.4) | 10 (100.0) | 11 (100.0) |
Age, yearsa | 53.4 (15.6) | 51.5 (17.5) | 54.4 (15.3) |
Duration of renal disease, yearsb | 5.0 (1.0-41.0) | 4.0 (1.0-21.0) | 9.0 (1.0-41.0) |
Duration of dialysis, monthsb | 17.0 (6.0-107.0) | 11.0 (6.0-87.0) | 13.0 (6.0-107.0) |
Previous transplant, n (%) | 8 (20.5) | 2 (20.0) | 3 (27.3) |